Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

141. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. (PubMed)

Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.  To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. Retrospective cohort study. Large US administrative database between 1 January 2010 and 31 December 2014. 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L. Thyroid hormone therapy (...) . Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes. Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P<0.01). Pregnancy loss was significantly less common among treated women (n=89; 10.6%) than among untreated women (n=614; 13.5%) (P<0.01). Compared

Full Text available with Trip Pro

2017 BMJ

142. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up (PubMed)

Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up Trends toward more conservative management of papillary thyroid cancer (PTC) diminish the primacy of serum thyroglobulin (Tg) assays as a posttreatment surveillance tool.To identify thyroid tumor-associated microRNAs (miRNAs) in the serum with potential for development as unique biomarkers of PTC recurrence.We measured expression of 754 miRNAs in serum samples collected from 11 (...) patients with PTC before and 30 days after thyroidectomy. Major candidates were then re-evaluated by absolute quantitative polymerase chain reaction analysis in an independent cohort of patients with PTC (n = 44) or benign nodules and 20 healthy controls (HCs). The 2 miRNAs most significantly associated with thyroid tumors were then assessed in matched serum samples (before and 30 days and 1 to 2 years after surgery) from the 20 PTC patients with complete follow-up datasets and results correlated

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

143. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive iodine (RAI). Methods Patients with WDTC were identified from SEER registries. Competing risk regression analysis was performed to calculate the risks of SHMs that occurred after WDTC treatment

2017 EvidenceUpdates

144. Afirma thyroid FNA analysis (Veracyte)

Afirma thyroid FNA analysis (Veracyte) Afirma thyroid FNA analysis (Veracyte) Afirma thyroid FNA analysis (Veracyte) HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Afirma thyroid FNA analysis (Veracyte) Lansdale: HAYES, Inc. Genetic Testing Publication. 2017 Authors' conclusions In recent years, significant advances in understanding (...) the genetic mechanisms of thyroid cancer have changed the way thyroid nodules are treated clinically. Several molecular targets have been associated with malignancy, including microRNA (miRNA), a noncoding endogenous form of RNA that helps regulate gene expression. Previous investigations have detected the dysregulation of miRNAs in malignant thyroid nodules, identifying the potential role of miRNAs in differentiating benign thyroid nodules from malignant ones. The Afirma Thyroid FNA Analysis

2017 Health Technology Assessment (HTA) Database.

159. Metastatic thyroid cancer - American Thyroid Association (ATA) guidelines

Metastatic thyroid cancer - American Thyroid Association (ATA) guidelines

2017 DynaMed Plus